Current state and challenges in developing oral vaccines

被引:449
作者
Ramirez, Julia E. Vela [1 ,2 ]
Sharpe, Lindsey A. [1 ,2 ]
Peppas, Nicholas A. [1 ,2 ,3 ,4 ,5 ]
机构
[1] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA
[2] Univ Texas Austin, Inst Biomat Drug Delivery & Regenerat Med, Austin, TX 78712 USA
[3] Univ Texas Austin, McKetta Dept Chem Engn, Austin, TX 78712 USA
[4] Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX 78712 USA
[5] Univ Texas Austin, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA
基金
美国国家科学基金会;
关键词
Oral vaccines; Adjuvants; Oral delivery; Protein delivery; Mucosal immunization; PLGA-BASED NANOPARTICLES; ENTERIC-COATED CAPSULES; PATCH M-CELLS; IN-VITRO; CHITOSAN NANOPARTICLES; MUCOSAL VACCINES; IMMUNE-RESPONSE; DRUG-DELIVERY; BIODEGRADABLE MICROPARTICLES; GASTROINTESTINAL-TRACT;
D O I
10.1016/j.addr.2017.04.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
While vaccination remains the most cost effective strategy for disease prevention, communicable diseases persist as the second leading cause of death worldwide. There is a need to design safe, novel vaccine delivery methods to protect against unaddressed and emerging diseases. Development of vaccines administered orally is preferable to traditional injection-based formulations for numerous reasons including improved safety and compliance, and easier manufacturing and administration. Additionally, the oral route enables stimulation of humoral and cellular immune responses at both systemic and mucosal sites to establish broader and long-lasting protection. However, oral delivery is challenging, requiring formulations to overcome the harsh gastrointestinal (GI) environment and avoid tolerance induction to achieve effective protection. Here we address the rationale for oral vaccines, including key biological and physicochemical considerations for next-generation oral vaccine design. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:116 / 131
页数:16
相关论文
共 214 条
[1]   Liposome: classification, preparation, and applications [J].
Akbarzadeh, Abolfazl ;
Rezaei-Sadabady, Rogaie ;
Davaran, Soodabeh ;
Joo, Sang Woo ;
Zarghami, Nosratollah ;
Hanifehpour, Younes ;
Samiei, Mohammad ;
Kouhi, Mohammad ;
Nejati-Koshki, Kazem .
NANOSCALE RESEARCH LETTERS, 2013, 8
[2]  
Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
[3]   Vaccine policy changes and epidemiology of poliomyelitis in the United States [J].
Alexander, LN ;
Seward, JF ;
Santibanez, TA ;
Pallansch, MA ;
Kew, OM ;
Prevots, DR ;
Strebel, PM ;
Cono, J ;
Wharton, M ;
Orenstein, WA ;
Sutter, RW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (14) :1696-1701
[4]   Towards tailored vaccine delivery: Needs, challenges and perspectives [J].
Amorij, Jean-Pierre ;
Kersten, Gideon F. A. ;
Saluja, Vinay ;
Tonnis, Wouter F. ;
Hinrichs, Wouter L. J. ;
Slutter, Bram ;
Bal, Suzanne M. ;
Bouwstra, Joke A. ;
Huckriede, Anke ;
Jiskoot, Wim .
JOURNAL OF CONTROLLED RELEASE, 2012, 161 (02) :363-376
[5]  
[Anonymous], INTESTINAL ARCHITECT, DOI DOI 10.1016/j.ijpharm.2014.10.059
[6]  
[Anonymous], WASTE MANAGEMENT DIS, DOI DOI 10.3389/fcimb.2013.00013
[7]  
[Anonymous], TYP OF VACC
[8]  
[Anonymous], SUMM BAS REG ACT TEM
[9]  
[Anonymous], WHO POSITION PAPER
[10]  
[Anonymous], 2016, WHO CHOL